Last reviewed · How we verify

Dapsone; Tretinoin — Competitive Intelligence Brief

Dapsone; Tretinoin (Dapsone; Tretinoin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimicrobial/retinoid combination. Area: Dermatology.

marketed Antimicrobial/retinoid combination Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Dapsone; Tretinoin (Dapsone; Tretinoin) — Allergan. This combination of dapsone (an antimicrobial and anti-inflammatory agent) and tretinoin (a retinoid that promotes skin cell turnover) works synergistically to reduce inflammation and normalize skin cell differentiation in acne and rosacea.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Dapsone; Tretinoin TARGET Dapsone; Tretinoin Allergan marketed Antimicrobial/retinoid combination

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimicrobial/retinoid combination class)

  1. Allergan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dapsone; Tretinoin — Competitive Intelligence Brief. https://druglandscape.com/ci/dapsone-tretinoin. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: